Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 5/20 | 0.39 |
| ▸ | BRAF | P15056 | 4/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161807 | 0.88 | KDR (0.52) | KDRPDE10ASCN9ACSNK1DCSNK1A1 | |
| SCHEMBL4170813 | 0.87 | PDE10A (0.45) | PDE10ACSNK1DCSNK1A1CBFBLMNA | |
| SCHEMBL4166878 | 0.85 | MGAM (0.49) | KDRPDE10ASCN9ACSNK1DCSNK1A1 | |
| SCHEMBL4164763 | 0.79 | KDR (0.54) | KDRPDE10ASCN9ACSNK1DCSNK1A1 | |
| SCHEMBL4173628 | 0.76 | PDE10A (0.43) | KDRPDE10ACSNK1DCSNK1A1RAF1 | |
| SCHEMBL972047 | 0.75 | TEK (0.72) | KDRPDE10ATEK | |
| SCHEMBL4158747 | 0.75 | KDR (0.59) | KDRPDE10ACSNK1DCSNK1A1RAF1 | |
| SCHEMBL4170820 | 0.75 | KDR (0.59) | KDRPDE10ACSNK1DCSNK1A1RAF1 | |
| SCHEMBL4364801 | 0.74 | RAF1 (0.58) | KDRPDE10ACSNK1DCSNK1A1RAF1 | |
| SCHEMBL4170611 | 0.74 | PDE10A (0.48) | KDRPDE10ACSNK1DCSNK1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | claimed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | claimed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | claimed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | claimed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | TIE1, KDR, FLT1 | KDR 2/4885PDE10A 4225/4885SCN9A 4418/4885 |
| US-20070066660-A1 | Benzimidazolyl derivatives | TIE1, ECE2, ABL1 | KDR 5/4885PDE10A 3571/4885SCN9A 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.